Chief Medical Officer · Olema Pharmaceuticals, Inc. (OLMA)

Naseem Zojwalla

A named executive officer of Olema Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,977,570

Salary $515,000

FY2023: $1,299,370

3rd of 3 named executive officers at Olema Pharmaceuticals by FY2024 total.

3 named officers on file for Olema Pharmaceuticals, FY2024

Naseem Zojwalla’s pay file — $29

  • 3 fiscal years of pay, line by line
  • OLMA’s disclosed peer group of 28 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Olema Pharmaceuticals’s whole pay program stands against its peers

  • Olema Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OLMA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-20.

Free

Get Naseem Zojwalla’s full pay file as a PDF — free

More than this page: up to 10 years of Naseem’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Naseem Zojwalla compensation by year

Olema Pharmaceuticals Summary Compensation Table · all 3 fiscal years held
In US dollars, as Olema Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$414,205$477,000$515,000
Bonus$150,000——
Stock awards$270,400——
Option awards$1,207,500$546,000$2,199,600
Non-equity incentive$198,000$262,000$248,000
Pension and deferred compensation$0$0$0
All other$13,272$14,370$14,970
Total$2,253,377$1,299,370$2,977,570

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Olema Pharmaceuticals, Inc. DEF 14A filed April 28, 2025, accession 0000950170-25-059348, and prior-year filings.

How this page was built: the Olema Pharmaceuticals, Inc. filed document, accession 0000950170-25-059348. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

$2.3M
$1.3M
$3.0M
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option67,709—$7.02
Option81,250—$4.87
Option195,000—$15.25

Per the Outstanding Equity Awards at Fiscal Year-End table in Olema Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

14 Form 4 lines since the FY2024 proxy (filed April 28, 2025)
current to 2026-11-20 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-02Grant or award derivative—250,000$0.00250,000
2026-02-02Grant or award derivative—106,250$0.00106,250
2025-12-23Exercise or conversion—50,000$7.02103,997
2025-12-23Sale—99,509$27.664,488
2025-12-23Exercise or conversion derivative—50,000$0.00156,818
2025-12-22Sale—100,000$28.0453,997
2025-12-22Exercise or conversion derivative—7,182$0.00206,818
2025-12-22Exercise or conversion—42,818$15.25146,815

The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Olema Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Sean BohenPresident and Chief Executive Officer$8,130,556
Shane KovacsChief Operating and Financial Officer$4,280,130
Naseem Zojwalla · this pageChief Medical Officer$2,977,570

The full Olema Pharmaceuticals compensation record

free company brief

This page is one person within Olema Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Olema Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Olema Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Naseem Zojwalla's compensation dossier · One-time report. No refunds.